Skip to content

Endometrium miR-22 and Tiam1/Rac1 signal pathway and embryo implantation failure in RIF-IVF

Endometrium miR-22 and Tiam1/Rac1 signal pathway and embryo implantation failure in RIF-IVF

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RO-14005046
Enrollment
Unknown
Registered
2014-08-02
Start date
2014-08-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF-RIF

Interventions

case series:IVF-RIF

Sponsors

1. Institute of Reproductive and Stem Cell Engineering, Central South University; 2. Reproductive and Genetic Hospital of Citic-Xiangya, Changsha, Hunan
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 35 Years

Inclusion criteria

Inclusion criteria: All IVF patients in study group and control group in this study were 22~35 years old, BMI being 18-23 kg/m2, menstrual regularity, 26-33 days period, and endometrium thickness with 8~14mm on the late proliferation phase detected by BUS in the nature menstrual cycle. No less than three cycle and six high quality embryos were transferred in total for every subject in study group who had been through at least three cycle IVF-embryo transfer failures. A good ovary reserve (FSH less than 8 mIU/ml, 5~12 antral follicle count per ovary), a good response to hormonal stimulation (more than eight oocytes/oocyte retrieval), a normal uterine cavity without intrauterine adhesion confirmed by hysteroscopy were required for all subjects of RIF-IVF in this study. Acquired infertile patients with fallopian tube obstruction at least one normal pregnancy and/or delivery were recruited in control group.

Exclusion criteria

Exclusion criteria: The patients with had hydrosalpinx, myoma of uterus, endometrial polyps, tuberculosis and inflammation, endometriosis, or PCOS was excluded. The patients had been screened for other cause such as karyotypic abnormalities and other inherited diseases, thyroid function abnormality, prolactinoma and other endocrine disease. The subjects were instructed not to use hormone therapy during the research cycle.

Design outcomes

Primary

MeasureTime frame
miR-22;Tiam1;Rac1;

Contacts

Public ContactMa Hailan
mahailan123@126.com+86 13907485529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026